ATE486088T1 - Hiv-impfstoff - Google Patents

Hiv-impfstoff

Info

Publication number
ATE486088T1
ATE486088T1 AT07722719T AT07722719T ATE486088T1 AT E486088 T1 ATE486088 T1 AT E486088T1 AT 07722719 T AT07722719 T AT 07722719T AT 07722719 T AT07722719 T AT 07722719T AT E486088 T1 ATE486088 T1 AT E486088T1
Authority
AT
Austria
Prior art keywords
composition
immunodeficiency virus
human immunodeficiency
medicament
manufacture
Prior art date
Application number
AT07722719T
Other languages
English (en)
Inventor
Anders Fomsgaard
Original Assignee
Statens Seruminstitut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Statens Seruminstitut filed Critical Statens Seruminstitut
Application granted granted Critical
Publication of ATE486088T1 publication Critical patent/ATE486088T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT07722719T 2006-06-01 2007-06-01 Hiv-impfstoff ATE486088T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200600750 2006-06-01
PCT/DK2007/050066 WO2007137591A2 (en) 2006-06-01 2007-06-01 Hiv vaccine

Publications (1)

Publication Number Publication Date
ATE486088T1 true ATE486088T1 (de) 2010-11-15

Family

ID=38617522

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07722719T ATE486088T1 (de) 2006-06-01 2007-06-01 Hiv-impfstoff

Country Status (4)

Country Link
EP (1) EP2021356B1 (de)
AT (1) ATE486088T1 (de)
DE (1) DE602007010127D1 (de)
WO (1) WO2007137591A2 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0805356D0 (en) * 2008-03-25 2008-04-30 Isis Innovation Vaccine adjuvant composition
WO2012041842A1 (en) * 2010-09-27 2012-04-05 Glaxosmithkline Biologicals S.A. Vaccine
US20150111836A1 (en) * 2012-02-12 2015-04-23 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Cellular apobec3 proteins and modulators thereof for regulating dna repair processes and treating proliferative diseases
EP2745845A1 (de) 2012-12-19 2014-06-25 Centre Hospitalier Universitaire de Bordeaux Verfahren zur Vorbeugung oder Behandlung einer HIV-Infektion
FR3086534B1 (fr) * 2018-10-01 2020-11-06 Univ Bordeaux Methode pour traiter une infection par le virus de l'immunodeficience humaine

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020182222A1 (en) * 1998-07-10 2002-12-05 Groot Anne De HIV vaccine candidate peptides
AU1075001A (en) * 1999-10-05 2001-05-10 Epimmune, Inc. Inducing cellular immune responses to human immunodeficiency virus-1 using peptide and nucleic acid compositions
CA2397998A1 (en) * 2000-01-28 2001-08-02 Statens Serum Institut Hiv peptides and nucleic acids encoding them for diagnosis and control of hiv infection

Also Published As

Publication number Publication date
EP2021356A2 (de) 2009-02-11
WO2007137591A8 (en) 2009-07-30
WO2007137591A3 (en) 2008-03-20
EP2021356B1 (de) 2010-10-27
DE602007010127D1 (en) 2010-12-09
WO2007137591A2 (en) 2007-12-06

Similar Documents

Publication Publication Date Title
EP3967323A3 (de) Hiv-impfstoff
NZ607477A (en) Non-natural amino acid replication-dependent microorganisms and vaccines
JP2018524335A5 (de)
EA201270108A1 (ru) Формирование полиспецифического t-клеточного ответа против вич у человека
JP2018521643A5 (de)
WO2020252393A8 (en) Compositions and methods for the treatment of human immunodeficiency virus
JP2013507107A5 (de)
CA2794632A1 (en) Bifunctional molecules for inactivating hiv and blocking hiv entry
DE602007010127D1 (en) Hiv-impfstoff
WO2008144584A3 (en) Cysteic acid derivatives of anti-viral peptides
IL182440A0 (en) Subtype-matched inactivated whole virus vaccines for treating patients with hiv infection
DE60136381D1 (de) Zusammensetzungen und verfahren zur modulierung von rsv-infektionen und -immunität
MX2012004409A (es) Proteina recombinante de humano cc10 para el tratamiento de la influenza.
MX354571B (es) Genomas lentivirales quimericos no integrativos como vacunas innovadoras contra el virus de la inmunodeficiencia humana tipo 1 (vih-1).
EA201290852A1 (ru) Комбинированная терапия, включающая антагонист ccr5, ингибитор протеазы вич-1 и фармакокинетический усилитель
US20140011735A1 (en) Antiviral composition
WO2010041237A3 (en) Cyclic v3 peptides for anti hiv-1 vaccine
JP2011521648A5 (de)
JP2014512353A5 (de)
NZ595060A (en) Treatment of cancer with immunostimulatory hiv tat derivative polypeptides
CY1115541T1 (el) Μεταλλαγμενη πρωτεϊνη τατ ουι για την προληψη ή την θεραπευτικη αντιμετωπιση του αids
EA201591095A1 (ru) Белок slurp-1 для применения в лечении глазных болезней
Avram et al. Evaluation of the therapeutic properties of mastoparan-and sifuvirtide-derivative antimicrobial peptides using chemical structure-function relationship-in vivo and in silico approaches
CA2350127A1 (en) Avipox vector coding an hiv antigen and a cytokine
Yuan et al. A 2B Protein‐Derived Peptide Effectively Inhibits Coxsackievirus B3 Infection

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties